Home › Compare › NWIFF vs ABBV
NWIFF yields 33112.58% · ABBV yields 3.06%● Live data
📍 NWIFF pulled ahead of the other in Year 1
Combined, NWIFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NWIFF + ABBV for your $10,000?
Nuinsco Resources Limited acquires, explores for, and evaluates properties for precious and base metals. The company primarily explores for gold, phosphate, niobium, tantalum, uranium, lithium, rubidium, rare earth elements, and other elements and compounds. It owns 100% interests in the Prairie Lake project that consists of 46 mining claims covering an area of 608 hectares located near Marathon, Ontario; and the Sunbeam gold property, which comprises 110 unpatented mining claims that covers an area of 48.8 square kilometers located to the town of northeast of Atikokan, Ontario. The company also holds an interest in the El Sid gold project located in the Eastern Desert of Egypt. In addition, it holds an option to acquire a 100% interest in the Dash lake project located in Fort Francis, Ontario; and Zig Zag lake project located in Armstrong, Ontario. Nuinsco Resources Limited is based in Toronto, Canada.
Full NWIFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.